Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma

NCT03540303 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT03540303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03540303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 12, 2018
Completion date
April 30, 2020
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed non hodgkin lymphoma